Department of Internal Medicine, University Tor Vergata of Rome, Rome, Italy.
Clin Sci (Lond). 2010 Mar 30;118(12):707-15. doi: 10.1042/CS20100027.
Gut inflammation occurring in patients with IBDs (inflammatory bowel diseases) is associated with exaggerated and poorly controlled T-cell-mediated immune responses, which are directed against normal components of the gut flora. T-cells accumulate in the inflamed gut of IBD patients as a result of multiple mechanisms, including enhanced recruitment of cells from the bloodstream, sustained cell cycling and diminished susceptibility of cells to undergo apoptosis. Activated T-cells produce huge amounts of cytokines, which contribute to amplify and sustain the ongoing mucosal inflammation. Strategies aimed at interfering with T-cell accumulation and/or function in the gut have been employed with clinical success in patients with IBDs. In the present article, we review the available results showing that T-cell-directed therapies are useful to dampen the tissue-damaging immune response in IBDs.
炎症性肠病（IBD）患者出现的肠道炎症与针对肠道正常菌群成分的过度和控制不良的 T 细胞介导的免疫反应有关。T 细胞通过多种机制在 IBD 患者的炎症肠道中积聚，包括从血液中增强细胞募集、持续的细胞周期和细胞对凋亡的敏感性降低。活化的 T 细胞产生大量细胞因子，有助于放大和维持持续的黏膜炎症。在 IBD 患者中，已经采用了旨在干扰肠道中 T 细胞积聚和/或功能的策略，并取得了临床成功。在本文中，我们回顾了现有的结果，表明针对 T 细胞的治疗方法可有效抑制 IBD 中的组织损伤免疫反应。
